singulargenomics.com (OMIC): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The price trend for Singular Genomics Systems (OMIC) shown on this GURU.Markets chart is driven by the promotion of G4 instruments and MaxRead kits, as well as the potential acquisition of Singular Genomics Systems (OMIC) by a large holding company, with EV/EBITDA standing at . The "razor-and-blade" model ensures steady revenue through the mandatory purchase of consumables. The platform's patent protection and the high cost of switching equipment create a powerful barrier to entry for new players.
Comprehensive metric breakdowns and analytics for singulargenomics.com (OMIC)
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Singular Genomics Systems|OMIC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Singular Genomics|OMIC - Company Total Indebtedness|Debts to Book Capitalization Singular Genomics Corp|OMIC - Long-Term Debt|Company Short-Term Debt Singular Genomics|Quick Liquidity singulargenomics.com
- financial results and valuation multiples details:
OMIC - Company Net Income|Expected Profit Singular Genomics Systems|OMIC - Price to Earnings Ratio|Forward P/E Multiple Singular Genomics Systems|OMIC - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Singular Genomics Corp|OMIC - Operating profit before deduction of amortization|Earnings per share for the last twelve months Singular Genomics|OMIC - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months singulargenomics.com|OMIC - Earnings per share increase in current year|Net earnings per share growth forecast for next year Singular Genomics Systems
Basic company analysis:Singular Genomics Systems Inc OMIC
Investors assess fundamental threats to capital through the ratio of enterprise value to EBITDA. For Singular Genomics (OMIC), which has pivoted from mass sales to niche B2B partnerships, this filter is critically important. By analyzing the EV/EBITDA trajectory of Singular Genomics (OMIC), one can determine to what extent the current market capitalization and debt are justified by the actual efficiency of the new cost-reduction strategy.
Competitor analysis
tempus.com - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Qiagen Corp QGEN|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNA: EV/EBITDA Multiple|CRISPR Therapeutics Inc (CRSP) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|RARE: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Enterprise Value to EBITDA Multiple 10x Genomics Inc|Intellia - EV/EBITDA Multiple|Company Value to EBITDA Stoke Corp|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation WVE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|Enterprise Value to EBITDA Ratio Taysha Corp TSHA|EV/EBITDA Multiple QURE (uniQure N.V.)|Total Company Value to Operating Income Before Depreciation Ratio meiragtx.com (MGTX)|REGENXBIO - EV/EBITDA Multiple|Solid Biosciences Inc (SLDB) - Enterprise Value to EBITDA Ratio|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PACB - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BNTC|DSGN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|Total Company Value to Operating Income Before Depreciation Ratio 4DMT|Lexeo Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Korro Bio Inc. (KRRO) - Company Value to EBITDA|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio silence-therapeutics.com SLN|PRQR (proqr.com) - Enterprise Value to EBITDA Ratio|CDXS: Enterprise Value to Operating Income Before Depreciation Ratio|SGMO (Sangamo) - EV/EBITDA Multiple|Company Value to EBITDA Nautilus Biotechnology Inc NAUT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|Enterprise Value to EBITDA Ratio precisionbiosciences.com DTIL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Generation Bio GBIO|Total Company Value to Operating Income Before Depreciation Ratio Boundless Bio Inc. (BOLD)|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Imunon, Inc.|phiopharma.com (PHIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Mustang Bio|RNAZ (TransCode Therapeutics Inc.) - EV/EBITDA Multiple|Bionano (BNGO) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APDN|Enterprise Value to EBITDA Ratio bluebird bio, Inc BLUE|EV/EBITDA Multiple IPA (ImmunoPrecise Antibodies Ltd.)|OMGA: Enterprise Value to Operating Income Before Depreciation|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SYRS (Syros Pharmaceuticals Inc.) - Enterprise Value to Operating Income Before Depreciation|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals, Inc (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
